Insider Selling: Tyme Technologies, Inc. (NASDAQ:TYME) Major Shareholder Sells 20,000 Shares of Stock

Tyme Technologies, Inc. (NASDAQ:TYME) major shareholder Michael Demurjian sold 20,000 shares of the business’s stock in a transaction on Monday, September 13th. The stock was sold at an average price of $1.04, for a total transaction of $20,800.00. Following the completion of the sale, the insider now owns 24,258,546 shares in the company, valued at approximately $25,228,887.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Michael Demurjian also recently made the following trade(s):

  • On Tuesday, September 7th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.12, for a total transaction of $22,400.00.
  • On Monday, August 30th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.10, for a total transaction of $22,000.00.
  • On Monday, August 23rd, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.03, for a total transaction of $20,600.00.
  • On Monday, August 16th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.02, for a total transaction of $20,400.00.
  • On Monday, July 26th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.53, for a total transaction of $30,600.00.
  • On Monday, July 19th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.02, for a total transaction of $20,400.00.
  • On Friday, June 18th, Michael Demurjian purchased 2,694 shares of Tyme Technologies stock. The stock was bought at an average cost of $2.82 per share, with a total value of $7,597.08.
  • On Monday, July 12th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.16, for a total transaction of $23,200.00.
  • On Tuesday, July 6th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.18, for a total transaction of $23,600.00.
  • On Monday, June 28th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.32, for a total transaction of $26,400.00.

TYME stock opened at $1.02 on Wednesday. The firm has a market cap of $175.65 million, a PE ratio of -5.67 and a beta of 0.94. The firm’s fifty day moving average is $1.11 and its 200 day moving average is $1.41. Tyme Technologies, Inc. has a one year low of $0.85 and a one year high of $4.99.

Tyme Technologies (NASDAQ:TYME) last released its quarterly earnings results on Tuesday, August 10th. The company reported ($0.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01).

Institutional investors and hedge funds have recently bought and sold shares of the business. LMR Partners LLP purchased a new position in Tyme Technologies during the second quarter valued at $33,000. Boothbay Fund Management LLC purchased a new position in Tyme Technologies during the second quarter valued at $37,000. New York State Common Retirement Fund lifted its holdings in Tyme Technologies by 185.7% during the first quarter. New York State Common Retirement Fund now owns 38,000 shares of the company’s stock valued at $68,000 after purchasing an additional 24,700 shares in the last quarter. Meitav Dash Investments Ltd. purchased a new position in Tyme Technologies during the first quarter valued at $69,000. Finally, Principal Financial Group Inc. lifted its holdings in Tyme Technologies by 169.3% during the second quarter. Principal Financial Group Inc. now owns 39,344 shares of the company’s stock valued at $50,000 after purchasing an additional 24,735 shares in the last quarter. 8.92% of the stock is currently owned by institutional investors and hedge funds.

Tyme Technologies Company Profile

Tyme Technologies, Inc operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell’s protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ.

Featured Story: Technical Analysis

Insider Buying and Selling by Quarter for Tyme Technologies (NASDAQ:TYME)

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.